Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Health Catalyst, Inc. (HCAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed provider of data and analytics technology and services to healthcare organizations, Health Catalyst uses these filings to report financial performance, governance decisions, and material corporate events.
Investors researching HCAT can review quarterly earnings information furnished on Form 8-K under Item 2.02, where Health Catalyst attaches its press releases and earnings release summaries for periods such as the quarters ended June 30 and September 30, 2025. These materials include segment revenue for Technology and Professional Services, gross profit and margins, adjusted gross profit, adjusted gross margin, adjusted EBITDA, and reconciliations of non-GAAP measures to the most directly comparable GAAP metrics.
Additional Form 8-K filings disclose executive and board changes under Item 5.02, such as the appointment of a President and Chief Operating Officer, the CEO’s planned retirement date, and the addition of new board members along with their compensation arrangements. Filings also summarize outcomes of the annual meeting of stockholders under Item 5.07, including director elections, ratification of the independent registered public accounting firm, and advisory votes on executive compensation and board declassification.
Beyond current reports on Form 8-K, Health Catalyst’s periodic reports on Forms 10-K and 10-Q, referenced in its press releases, contain detailed discussions of risk factors, management’s analysis of financial condition and results of operations, and disclosures about items such as stock-based compensation, acquisition-related costs, restructuring charges, and lease-related items.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain the key points of lengthy documents, such as annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K). Users can quickly see what changed in a filing, how segment results evolved, and which governance or compensation decisions were disclosed, while still having direct access to the full SEC documents for deeper review.
Health Catalyst insider sale tied to RSU tax withholding. Chief People Officer Linda Llewelyn reported a sale of 2,854 shares of Health Catalyst, Inc. (HCAT) on 09/02/2025 at $3.3627 per share. The filing states this sale was a mandated "sell-to-cover" to satisfy tax withholding on vested restricted stock units, not a discretionary trade. After the transaction, the reporting person beneficially owned 153,025 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,138 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax withholding from the vesting of restricted stock units. After the transaction, he beneficially owned 147,987 shares. The filing specifies this was a sell-to-cover required under the issuer's equity incentive plan and not a voluntary trade by the reporting person. The Form 4 is signed and dated 09/04/2025.
Health Catalyst, Inc. director Spencer Justin was granted 68,572 restricted stock units (RSUs) on 09/01/2025 under the company's 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock and the award was reported with a $0.00 per-share price, consistent with typical equity awards to directors.
The RSUs vest under the Non-Employee Director Compensation Policy: 33.33% vests on 09/01/2026 and the remaining 66.67% vests in two equal annual installments thereafter. The filing was made by one reporting person and signed by an attorney-in-fact on 09/03/2025.
Health Catalyst, Inc. director reports no share ownership
Spencer Justin, a director of Health Catalyst, Inc. (HCAT), filed an initial ownership report as required for insiders. The filing states in the remarks section that no securities are beneficially owned, and both the non-derivative and derivative ownership tables show no holdings. This indicates that, as of the event date of 09/01/2025, the director reports no direct or indirect ownership of Health Catalyst stock or related derivative securities.
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.
Health Catalyst, Inc. Form 144 summary: This notice reports a proposed sale of 4,578 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 with an aggregate market value of $15,394.44. The filing shows the shares were acquired as restricted stock from Health Catalyst, Inc. on 09/02/2025 as compensation. The filer previously sold 4,747 restricted shares on 06/02/2025 for gross proceeds of $17,254.40. The issuer's outstanding shares are listed as 70,373,625. Some filer identification fields (CIK/CCC and contact details) are not provided in the visible content.
Health Catalyst, Inc. (HCAT) Form 144 summary: This notice reports a proposed sale of 3,138 restricted common shares through Morgan Stanley Smith Barney on 09/02/2025, with an aggregate market value of $10,552.15. The filer acquired these shares as restricted stock on 09/02/2025 as compensation. The filing also discloses two restricted stock sales by the same person in the past three months: 3,255 shares sold on 06/02/2025 for $11,831.27 and 6,057 shares sold on 06/05/2025 for $23,890.63. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Health Catalyst, Inc. (HCAT) filing of Form 144 notifies the market that 2,613 shares of common stock will be offered for sale through Morgan Stanley Smith Barney on 09/02/2025. The filing lists an aggregate market value of $8,786.74 for the shares based on the transaction and shows 70,373,625 shares outstanding for the issuer.
The shares were acquired the same day, 09/02/2025, as restricted stock from Health Catalyst and are identified as compensation. The filer discloses a prior restricted-stock sale of 2,712 shares on 06/02/2025 yielding gross proceeds of $9,857.58. By signing, the person attests they are unaware of undisclosed material adverse information about the issuer.
Health Catalyst, Inc. (HCAT) Form 144 shows a proposed sale of 8,335 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 on the NASDAQ, with an aggregate market value of $28,028.10. The filing reports the shares were acquired the same day (09/02/2025) as restricted stock from Health Catalyst as compensation. The filer previously sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10. The total number of outstanding shares is listed as 70,373,625. By signing, the seller represents no undisclosed material adverse information about the issuer.
Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67. The shares were acquired the same day as restricted stock issued by Health Catalyst as compensation. The filing lists 70,373,625 shares outstanding and indicates no securities sold by the reporting person in the past three months. The filer certifies no undisclosed material adverse information and provides standard Form 144 representations.